<p>Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by the dysfunction of cilia, leading to respiratory and other systemic issues. The condition is often associated with chronic respiratory infections, sinusitis, and, in some cases, infertility.</p>
<h2><strong>PCD Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Primary Ciliary Dyskinesia in the 7MM from 2023 to 2034 includes:</p>
<ul>
<li>Total Prevalent Cases of Primary Ciliary Dyskinesia</li>
<li>Total Diagnosed Prevalent Cases of Primary Ciliary Dyskinesia</li>
<li>Age-specific Cases of Primary Ciliary Dyskinesia</li>
<li>Total Prevalence of Primary Ciliary Dyskinesia by Pathogenic variants in gene</li>
<li>Total Prevalence of Primary Ciliary Dyskinesia by Clinical Manifestations</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-epidemiology-forecast"><span style="text-decoration: underline;"><strong>PCD Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, the 7MM accounted for nearly 70,000 total prevalent cases of Primary Ciliary Dyskinesia.</li>
<li>In 2023, the United States accounted for nearly 1,800 diagnosed prevalent cases of Primary Ciliary Dyskinesia.</li>
<li>The prevalent cases of Primary Ciliary Dyskinesia by age are segmented into three categories:</li>
</ul>
<ul>
<li style="list-style-type: none;">
<ul style="list-style-type: circle;">
<li>0-5 years</li>
<li>6-20 years</li>
<li>21-40 years</li>
<li>40 years</li>
<li>Among all age groups, the 6-20 category accounted for the highest number of cases in the United States.</li>
</ul>
</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market"><span style="text-decoration: underline;"><strong>PCD Market</strong></span></a></h2>
<p>The total market size of Primary Ciliary Dyskinesia in 2023 was approximately USD 101 million in the 7MM.</p>
<h2>PCD Market Drivers</h2>
<ul>
<li>Growing awareness about PCD and improved diagnostic techniques have led to better identification and management of the disease.</li>
<li>Increasing research and development focused on gene therapy and targeted treatments.</li>
</ul>
<h2>PCD Market Barriers</h2>
<ul>
<li>PCD remains a relatively under-diagnosed condition due to its diverse manifestations and symptom overlap with other respiratory conditions.</li>
<li>The limited availability of specialized treatment options hinders the management of the disease in certain regions.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight"><span style="text-decoration: underline;"><strong>PCD Emerging Therapies</strong></span></a></h2>
<ul>
<li>P-1037</li>
<li>RCT1100</li>
<li>ETH 42</li>
<li>CIL-05</li>
<li>ETH 43</li>
<li>ETH 44</li>
</ul>
<p>And others</p>
<h2><strong>PCD Key Players</strong></h2>
<ul>
<li>Parion Sciences</li>
<li>ReCode Therapeutics</li>
<li>Ethris</li>
<li>Cila Therapeutics</li>
<li>ReCode Therapeutics</li>
</ul>
<p>And others</p>

Primary Ciliary Dyskinesia Market Infographic

Primary Ciliary Dyskinesia Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.